Last updated: August 19, 2026
Mucus Relief DM Extended Release Caplets are an over-the-counter combination product containing guaifenesin, an expectorant, and dextromethorphan hydrobromide, an antitussive. The standard extended-release strength is 600 mg guaifenesin and 30 mg dextromethorphan hydrobromide per caplet, dosed every 12 hours. The product’s commercial value depends less on active-ingredient exclusivity than on low-cost extended-release manufacturing, reliable dissolution performance, private-label distribution and retail price positioning.
The core formulation has limited patent defensibility. The strongest commercial opportunities are in excipient optimization, process control, packaging, retailer-specific versions and differentiated delivery formats rather than in broad composition-of-matter protection.
What is Mucus Relief DM Extended Release?
Mucus Relief DM Extended Release is a dual-active OTC cough and mucus product.
| Product characteristic |
Typical specification |
| Expectorant |
Guaifenesin, 600 mg |
| Antitussive |
Dextromethorphan hydrobromide, 30 mg |
| Dosage form |
Extended-release caplet |
| Dosing interval |
Every 12 hours |
| Regulatory category |
OTC drug |
| Primary therapeutic claims |
Relieves chest congestion and suppresses cough |
| Reference-category competitor |
Mucinex DM Extended Release |
| Principal manufacturing challenge |
Maintaining 12-hour release for both actives in a compact caplet |
DailyMed labeling identifies guaifenesin and dextromethorphan hydrobromide as the active ingredients in products sold under the Mucus Relief DM name. Exact inactive ingredients can vary by labeler, manufacturer, strength and market channel.[1]
The product is generally positioned as a store-brand or value alternative to branded guaifenesin/dextromethorphan products. The commercial model is based on high-volume seasonal demand, retailer distribution and manufacturing cost control.
What excipients are used in Mucus Relief DM Extended Release Caplets?
Public labels for equivalent products commonly identify a matrix-based formulation containing hypromellose and standard tableting excipients. A representative excipient system may include:
| Excipient class |
Likely function |
| Hypromellose |
Hydrophilic release-controlling matrix |
| Microcrystalline cellulose |
Diluent and compression aid |
| Povidone |
Binder |
| Crospovidone or sodium starch glycolate |
Disintegrant, where included |
| Magnesium stearate |
Lubricant |
| Colloidal silicon dioxide |
Glidant |
| Stearic acid |
Lubricant or compression aid |
| Film-coating polymers |
Protection, appearance and swallowability |
| Colorants |
Product identification and retail differentiation |
The exact formula should be taken from the applicable FDA label or NDC record before making a manufacturing, licensing or patent decision. Store-brand products frequently use more than one contract manufacturer, and the inactive-ingredient list can change after site transfers or reformulation.
How does hypromellose control release?
Hypromellose is the most commercially important excipient in this product class. After ingestion, the polymer hydrates and forms a gel layer around the caplet. Water penetrates the matrix, the actives dissolve, and the dissolved drug diffuses through the hydrated polymer. Matrix erosion can contribute to later-stage release.
The performance of hypromellose depends on:
- Polymer viscosity grade
- Substitution type
- Particle size
- Polymer concentration
- Granulation method
- Compression force
- Tablet porosity
- Drug-to-polymer ratio
- Dissolution medium and agitation conditions
A higher-viscosity polymer generally slows release but can increase tablet size, hardness and manufacturing sensitivity. Lower-viscosity grades may improve processing and reduce residual matrix material but can produce an early release surge if the formulation lacks sufficient gel strength.
Why does the dual-active combination create formulation risk?
Guaifenesin is present at a comparatively high dose, while dextromethorphan hydrobromide is present at a much lower dose. The formulation must deliver both actives over the target interval despite differences in solubility, particle properties and dose fraction.
A single homogeneous matrix can simplify manufacturing, but it may not optimize release for both ingredients. A layered or multiparticulate design can provide greater control, although it raises tooling, validation and cost requirements.
What excipient strategy best supports a 12-hour caplet?
A commercially efficient strategy is a robust hydrophilic matrix with a narrow excipient count and broad raw-material availability.
Base formulation strategy
The preferred development sequence is:
- Establish a guaifenesin-rich matrix using hypromellose and a compressible diluent.
- Add the lower-dose dextromethorphan component through geometric dilution or controlled premixing.
- Optimize polymer grade and loading against dissolution targets.
- Use a low-level lubricant system that does not impair wetting.
- Apply a thin film coating for handling, identification and swallowability.
- Confirm stability under accelerated and long-term conditions.
The primary development target should be dissolution robustness rather than the lowest possible polymer loading. A formulation that passes only at nominal compression force may generate manufacturing failures when tooling wear, granule moisture or lubricant mixing changes.
Excipient trade-offs
| Strategy |
Benefits |
Commercial risks |
| Single hypromellose matrix |
Low tooling and process complexity |
Less flexibility for separate active release rates |
| Multi-grade hypromellose system |
Better control across early and late release |
More supplier and blending complexity |
| Hydrophilic polymer plus insoluble matrix former |
Can reduce dose dumping |
Possible incomplete release or food-effect sensitivity |
| Bilayer caplet |
Separate control of the two actives |
Higher capital and validation burden |
| Multiparticulate coating |
Strong release control and formulation flexibility |
Higher coating cost and capsule or compression complexity |
| High-polymer matrix |
Greater release margin |
Larger caplet and slower development |
| Low-polymer matrix |
Lower cost and smaller tablet |
Higher risk of burst release and batch variability |
The optimal commercial formulation is likely a conventional compressed matrix caplet, not a complex multiparticulate system. The branded benchmark creates a performance expectation, but the value segment generally rewards manufacturing simplicity and reliable supply.
What regulatory status applies to Mucus Relief DM?
Mucus Relief DM is regulated as an OTC drug rather than as a prescription product. FDA OTC monograph requirements govern the active ingredients, labeling, dosage and permitted claims when the formulation falls within the applicable monograph conditions.[2]
The product typically requires:
- FDA-compliant Drug Facts labeling
- An establishment registration
- Product listing and NDC assignment
- Current good manufacturing practice compliance
- Stability data supporting the labeled shelf life
- Finished-product identity, assay, content uniformity and dissolution testing
- Validation of the extended-release manufacturing process
The product does not normally require an approved NDA when marketed under the applicable OTC monograph framework. An OTC product outside monograph conditions may require an approved application or another FDA pathway.
What is the Orange Book status?
Mucus Relief DM is generally not an Orange Book-listed prescription product. The Orange Book primarily identifies approved prescription drug products with therapeutic-equivalence information and related patent or exclusivity data.[3]
As a result:
- There is generally no Orange Book patent-listing process for this OTC SKU.
- ANDA Paragraph IV challenges are not the normal route for competing OTC monograph products.
- Generic entry is driven by monograph compliance, manufacturing capability, retailer procurement and trademark restrictions.
- A competitor does not need to invalidate an Orange Book-listed patent to launch a compliant private-label product.
What patents protect Mucus Relief DM Extended Release Caplets?
The active ingredients are old, widely used OTC compounds and do not have meaningful composition-of-matter exclusivity. Broad protection for guaifenesin or dextromethorphan is not a practical barrier to entry.
Potentially relevant patents could cover:
- Specific polymer combinations
- Defined dissolution profiles
- Bilayer or multilayer structures
- Taste masking
- Coating systems
- Abuse-deterrent configurations
- Manufacturing processes
- Moisture-control packaging
- Combination dosage forms
Those rights would be formulation-specific and would not necessarily block a competitor using a different matrix system.
The likely patent position is therefore:
| IP category |
Barrier level |
| Active-ingredient patents |
Very low |
| Broad combination patents |
Low |
| Conventional hypromellose matrix |
Low |
| Narrow dissolution-profile patents |
Low to moderate |
| Novel multilayer or multiparticulate system |
Moderate |
| Manufacturing-process patents |
Moderate if process-specific |
| Trademark and trade dress |
Commercially relevant |
| Trade secrets and supplier know-how |
Relevant to execution |
No conventional Paragraph IV litigation pathway is expected for the named OTC product. Patent litigation could still occur over a proprietary formulation or process, but the central commercial risk is more likely to involve trademark, contract manufacturing, quality or retailer competition than Orange Book litigation.
When does Mucus Relief DM lose exclusivity?
The product has no meaningful product-specific prescription exclusivity period comparable to an NDA product. Its commercial exclusivity is effectively absent if the active ingredients, strength, claims, dosage form and labeling comply with the OTC monograph.
The relevant barriers are:
- Retailer authorization
- Private-label supply agreements
- Manufacturing qualification
- Product quality history
- Seasonal inventory planning
- Brand recognition
- Trademark rights
- Any narrow formulation patent that remains enforceable
A new entrant can generally compete without waiting for patent expiry, provided it does not copy protected branding, trade dress or a patented formulation.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can create value in four areas.
1. Higher-performance release matrices
A supplier can position a high-viscosity hypromellose grade or co-processed matrix excipient as a way to reduce dissolution variability. The strongest sales proposition is batch-to-batch robustness, not simply a lower excipient price.
Useful development claims include:
- Reduced sensitivity to compression force
- Consistent release across tablet hardness ranges
- Lower risk of early release
- Improved scale-up from pilot to commercial batches
- Better compatibility with direct compression
2. Smaller caplets
The caplet has a high guaifenesin load. A more efficient matrix can reduce tablet mass while preserving 12-hour performance. Smaller size can improve swallowability and support premium positioning.
Potential approaches include:
- Higher-efficiency matrix polymers
- Co-processed excipients
- Improved particle engineering
- Granulation that increases bulk density
- Lower-dose coating systems
- Optimized lubricant levels
Size reduction must not compromise mechanical strength or dissolution.
3. Alternative delivery formats
Commercially differentiated formats may include:
- Smaller swallowable caplets
- Liquid-filled or softgel products
- Sprinkleable multiparticulates
- Orally disintegrating formats, subject to release-control feasibility
- Pediatric products with age-appropriate labeling
- Unit-dose blister packs
- Travel-size packaging
A 12-hour extended-release product is difficult to convert into an orally disintegrating format without creating an early-release problem. Multiparticulate coating may offer a more credible path than a conventional fast-disintegrating tablet.
4. Label-friendly excipient systems
Some retailers and consumers prefer products without artificial colors, certain coatings, animal-derived materials or selected allergens. A supplier that can provide a validated, low-risk excipient package may support retailer-specific reformulation.
The commercial opportunity is strongest when the excipient system reduces development time and regulatory documentation rather than merely replacing one commodity excipient with another.
What manufacturing and IP barriers affect market entry?
Manufacturing barriers are moderate but manageable.
Critical process risks include:
- Segregation of the low-dose dextromethorphan component
- Over-lubrication and reduced dissolution
- Variable granule moisture
- Inadequate polymer hydration
- Caplet capping or lamination
- High compression-force sensitivity
- Dissolution drift during scale-up
- Film-coat defects
- Packaging-related moisture uptake
A robust control strategy should link critical material attributes to dissolution. The most important variables are polymer viscosity, polymer particle size, granule density, lubricant blending time, tablet porosity and coating weight.
Packaging is part of the formulation strategy. High-barrier bottles with induction seals or unit-dose blister packs can reduce moisture exposure and protect caplet appearance. Packaging differentiation may be patentable in narrow circumstances, but it is more often protected through know-how, supplier qualification and trade dress.
How does Mucus Relief DM compare with Mucinex DM?
Mucinex DM is the principal branded benchmark in the same therapeutic category. Mucus Relief DM competes through lower price and retailer distribution.
| Factor |
Mucus Relief DM |
Mucinex DM |
| Business model |
Store brand or value product |
Branded OTC product |
| Active ingredients |
Guaifenesin and dextromethorphan |
Guaifenesin and dextromethorphan |
| Core dosage form |
Extended-release caplet or tablet |
Extended-release tablet |
| Primary advantage |
Price and retailer access |
Brand recognition and consumer demand |
| Patent barrier |
Limited for conventional formulation |
Product-specific rights may exist, but broad entry barriers are limited |
| Main competitive lever |
Cost, supply and private-label placement |
Marketing, brand equity and distribution |
| Licensing relevance |
Contract manufacturing and retailer supply |
Brand, manufacturing and distribution rights |
A private-label entrant does not need to replicate the branded product’s excipient profile. It needs to deliver an acceptable dissolution profile, stability package, caplet quality and consumer experience while avoiding protected branding and any enforceable narrow formulation claims.
Are biosimilar or biologic risks relevant?
No. Mucus Relief DM contains small-molecule OTC actives, not a biologic. Biosimilar approval, biologic patent dance procedures and biologic exclusivity periods do not apply.
Competitive risk comes from other OTC combination products, single-ingredient guaifenesin products, dextromethorphan products, liquids, lozenges and retailer-controlled private labels.
What licensing opportunities exist?
No product-specific licensing deal is inherent in the Mucus Relief DM name. The most relevant commercial arrangements are:
- Retailer-private-label supply contracts
- Contract manufacturing agreements
- Excipient supply and technical-service agreements
- Brand licensing for an established OTC trademark
- Geographic distribution agreements
- Technology licenses for novel extended-release matrices
- Co-development agreements for smaller caplets or alternative formats
A formulation license is commercially attractive only if it produces a measurable advantage, such as a smaller caplet, improved dissolution robustness, lower cost or a differentiated release profile. A conventional hypromellose matrix alone is unlikely to support significant royalty economics.
Key Takeaways
- Mucus Relief DM Extended Release Caplets typically combine 600 mg guaifenesin with 30 mg dextromethorphan hydrobromide.
- Hypromellose is the central release-controlling excipient in the conventional formulation.
- The core product has limited active-ingredient patent protection and generally does not rely on Orange Book exclusivity.
- Paragraph IV litigation is not the normal competitive pathway for this OTC product.
- The strongest formulation opportunities are smaller caplets, improved dissolution robustness, alternative delivery formats and label-friendly excipient systems.
- Manufacturing know-how, retailer access, supply reliability and trademark protection are more important than broad patent exclusivity.
- Biosimilar risk does not apply.
- The highest-value licensing opportunities involve validated delivery technology or retailer-scale private-label supply, not ordinary commodity excipient substitution.
FAQs
Can a competitor launch a guaifenesin and dextromethorphan extended-release product without an ANDA?
Yes. A compliant OTC monograph product generally does not require an ANDA. The manufacturer must satisfy FDA monograph, labeling, quality and cGMP requirements.
Is hypromellose patent-protected in Mucus Relief DM?
Hypromellose itself is a long-established pharmaceutical excipient. A particular concentration, grade combination, release profile or manufacturing process could be claimed in a narrow patent, but ordinary use of hypromellose is not a meaningful product barrier.
Can a smaller caplet be patented?
Potentially. Patentability would depend on technical features such as a defined polymer architecture, dissolution performance, tablet geometry or manufacturing process. A smaller tablet alone would generally provide weak protection without an unexpected technical result.
Does a change in excipients require a new FDA submission?
The regulatory impact depends on the product’s monograph status, labeler, manufacturing change and effect on quality attributes. A reformulation must be supported by appropriate quality, stability and dissolution data and handled under the applicable FDA change-control requirements.
What is the most attractive commercial differentiation for this product?
A smaller, easier-to-swallow 12-hour caplet with reliable dissolution and competitive cost is the most practical differentiation strategy. Unit-dose packaging and retailer-specific labeling can add commercial value without requiring a complex new drug-delivery platform.
References
-
U.S. National Library of Medicine. (n.d.). DailyMed: Mucus Relief DM, dextromethorphan hydrobromide and guaifenesin tablet, extended release. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). OTC monograph M012: Cough, cold, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.
